Authors
Dib Sassine, Ling Chen, Xiao Xu, Jennifer S Ferris, Shayan Dioun, Caryn M S Clair, Dawn L Hershman, June Y Hou, Jason D Wright
Published in
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. Volume 36. Issue 12. Pages 105640. Sep 29, 2026. Epub Sep 29, 2026.
Abstract
To compare the incidence and temporal distribution of venous thromboembolism in patients with distant-stage uterine cancer treated with primary cytoreductive surgery followed by adjuvant chemotherapy versus neoadjuvant chemotherapy followed by interval cytoreductive surgery.
This retrospective cohort study used the Surveillance, Epidemiology, and End Results Program-Medicare data to identify women aged ≥65 years with Surveillance, Epidemiology, and End Results Program Summary Stage distant uterine cancer diagnosed from 2008 to 2017 who underwent both hysterectomy and chemotherapy within 6 months of diagnosis. Treatment was classified by the sequence of surgery and chemotherapy within 6 months of diagnosis. Venous thromboembolism, comprising pulmonary embolism and deep vein thrombosis, was identified from claims. Patients with baseline venous thromboembolism (6 months before through the month of diagnosis) were excluded from the primary analysis. Cumulative venous thromboembolism incidence was estimated using competing risk methods (death as a competing event) and compared via Gray's test. Multi-variable analysis evaluated factors associated with venous thromboembolism during the first 6 months after diagnosis, adjusting for demographic, clinical, and tumor characteristics. Landmark, time-varying treatment-phase, and first-treatment-anchored sensitivity analyses were performed to address immortal time and time-zero misalignment.
Of 1977 patients, 186 (9.4%) had venous thromboembolism prior to diagnosis and were excluded, leaving 1791 patients for analysis: 74.7% underwent primary cytoreductive surgery and 25.3% received neoadjuvant chemotherapy. Neoadjuvant chemotherapy use increased from 17.6% (2008) to 35.5% (2017). Neoadjuvant chemotherapy patients had higher baseline venous thromboembolism prevalence (14.7% vs 7.5%, p<.001) and comorbidity burden. Overall, 568 venous thromboembolism events occurred; cumulative venous thromboembolism incidence was 20.1% at 6 months, 33.6% at 24 months, and 49.3% at 60 months. Neoadjuvant chemotherapy patients had higher early cumulative venous thromboembolism incidence (23.0% vs 19.1% at 6 months; 40.8% vs 31.5% at 24 months), with convergence by 60 months (46.5% vs 49.2%; Gray's test p=.054). In multi-variable analysis, the adjusted risk ratio for early venous thromboembolism with neoadjuvant chemotherapy versus primary cytoreductive surgery was 1.21 (95% confidence interval 0.97-1.51), an imprecise estimate that does not exclude a clinically meaningful increase in early risk.
Among older patients with distant-stage uterine cancer, venous thromboembolism was common, affecting approximately 1 in 5 patients within 6 months and nearly 1 in 2 within 5 years. The cumulative venous thromboembolism incidence did not differ significantly between primary cytoreductive surgery and neoadjuvant chemotherapy. Events occurred earlier in the neoadjuvant chemotherapy group, a pattern that may reflect baseline differences between the groups and differential ascertainment as much as treatment sequence. Our findings support the need for a prospective evaluation of treatment-phase-specific thromboprophylaxis.
PMID:
42950581
Bibliographic data and abstract were imported from PubMed on 29 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 12
- Comments 0